Research Article

The Lipodystrophy Syndrome in HIV-Infected Children under Antiretroviral Therapy: A First Report from the Central Africa

Honoré Kalombayi Tshamala,1 Loukia Aketi,1 Pierre Manianga Tshibassu,2 Mathilde Bothale Ekila,3 Eric Musalu Mafuta,4 Patrick Kalambayi Kayembe,4 Michel Ntetani Aloni5, and Joseph Diayisu Shiku1

1Division of Cardiology and Infectious Diseases, Department of Pediatrics, University Hospital of Kinshasa, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
2Division of Neurology, Nutrition and Gastroenterology, Department of Paediatrics, University Hospital of Kinshasa, School of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
3Division of Infectious Diseases, Department of Internal Medicine, University Hospital of Kinshasa, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
4Division of Biostatistics and Epidemiology, School of Public Health, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
5Division of Hemato-Oncology and Nephrology, Department of Pediatrics, University Hospital of Kinshasa, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo

Correspondence should be addressed to Michel Ntetani Aloni; michelaloni2003@yahoo.fr

Received 21 May 2018; Revised 30 October 2018; Accepted 1 January 2019; Published 3 March 2019

Academic Editor: Steven E. Lipshultz

Copyright © 2019 Honoré Kalombayi Tshamala et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Despite the high prevalence of the HIV/AIDS, few studies focused on the prevalence of lipodystrophy in pediatric HIV patients on antiretroviral therapy (ART) in sub-Saharan African countries. The aim of this study was to assess the prevalence and to identify the risk factors of metabolic disorders related to ART therapy in this population. Methods. A cross-sectional study was completed in Kinshasa, the Democratic Republic of Congo. HIV-infected children aged between six and 18 years on ART were consecutively recruited. For each case, two control children (one non-HIV infected child and one HIV-infected antiretroviral therapy-naïve child) were also recruited. Results. 80 HIV-infected on ART therapy children (group 1), 80 noninfected children (group 2) and 65 HIV-infected antiretroviral therapy-naive children (group 3) were recruited. The frequency of lipoatrophy was not statistically different between group 1 (16.3%) and group 3 (21.5%). A significantly higher proportion of lipohypertrophy, hypercholesterolemia, and lactic acidosis was noted in children of group 1, compared to the controls (p<0.05). Mixed form was rarely observed in this series. The frequency of hypertriglyceridemia was not different between the 3 groups (p>0.05). Conclusion. Lipohypertrophpy, hypercholesterolemia, and lactic acidosis emerge as a frequent metabolic disorders due to ART therapy.

1. Introduction

The introduction of antiretroviral (ART) therapy has greatly reduced morbidity and mortality and improved the quality and life expectancy of pediatric HIV patients [1]. However, lipodystrophy and dyslipidemia are common in pediatric HIV patients receiving ART therapy and lipid profile may include an isolated elevation of triglycerides or cholesterol or a combination of both with various modifications of the concentration of cholesterol of low (LDL-c) or high (HDL-c) [2] density. These different risk factors may act as metabolic syndrome on the cardiovascular system [2]. However, studies conducted mainly in developed countries have reported conflicting results regarding the association between ART therapy and the incidence of lipodystrophy and dyslipidemia in pediatric HIV patients [3]. These complications are particularly associated with the use of the protease inhibitors [2].
Sub-Saharan Africa contributes significantly to the high global rate of morbidity and mortality reported in HIV infection [4]. In the Democratic Republic of Congo (DRC), the overall prevalence of HIV was 4% and 37,000–52,000 pediatric HIV patients were less than fifteen years of age [4]. Despite this high prevalence of the disease and the risk of cardiovascular disease, very few studies focused on the prevalence of lipodystrophy in pediatric HIV patients on ARV therapy that have been reported in sub-Saharan African countries [5–7]. Further information on metabolic complications for HIV-infected children in this part of the world is urgently needed. We therefore conducted a cross-sectional study in pediatric HIV patients on ARV therapy. The aim of this study was to assess the prevalence of metabolic abnormalities and their phenotypic expression as lipodystrophy in HIV-infected children receiving ARVs compared with HIV-infected children not on ARVs and to HIV-negative children.

2. Methods

2.1. Study Setting and Design. The cross-sectional study was completed between March 2011 and September 2013 in five health institutions located in Kinshasa, the large city and capital of the DRC. The primary hospital was the University Hospital of Kinshasa and four secondary-care hospitals, Centre Médical Monkole, Centre de Santé AMOCONGO, Bomoyi Center of Kingsani, and Saint Joseph Hospital. These hospitals provide most of the nonprivate pediatric beds in the city:

HIV-infected children aged between six and 18 years on antiretroviral therapy for at least one year were consecutively recruited. For each case, two control children (one non-HIV infected child and one HIV-infected antiretroviral therapy-naive child) matched for age, sex, and place of residence were also recruited into the study. A complete physical examination was carried out on each child by a pediatrician. Children were excluded where they had drugs which can induce hypertension or change carbohydrate metabolism.

2.2. Data and Sample Collection. The following formula was used to estimate the minimum size of the study population:

\[ n = \frac{Z^2pq}{d^2} \]

\( n \) = sample size; \( Z \) = confidence level at 95% (1.96); \( p \) = proportion of the target population with lipodystrophy. The prevalence of 18% found recently in the literature was the reference value for this study [8]. \( q \) = proportion of the target population without the characteristic of the study population (0.82); \( d \) = degree of accuracy (0.10). The minimum sample size was estimated at 56 children. In this study, our sample consists of 225 children who were recruited. Among them, there were 80 HIV-infected on ARV therapy children (group 1), 80 noninfected children (group 2), and 65 HIV-infected antiretroviral therapy-naive children (group 3). Overall median age was 11.1 ± 3.4 years.

2.3. Clinical Features and Laboratory Analysis. The following information was recorded and analyzed: (i) demographic characteristics such as age and gender, (ii) triceps skinfold and Body Mass Index (BMI), (iii) clinical features, and (iv) laboratories investigations including total cholesterol, triglyceride, HDL, and LDL-cholesterol.

Height (cm) and weight (kg) were measured for each selected patient. BMI was calculated (BMI = weight/height^2) (Kg/m^2).

Diagnosis of HIV infection was made by using two antibody detection tests (Determine® and Unigold®) for those older than 18 months, according to World Health Organization strategy (WHO) and the National Program against HIV (PNLS) of the DRC. The CD4 rate was measured in all HIV-positive children (HIV-positive cases and control group). HIV infection clinical stage was detected using the World Health Organization (WHO) clinical classification of HIV/AIDS in infants and children [9].

Total cholesterol, triglyceride, High Density Lipoprotein (HDL), and Low Density Lipoprotein- (LDL-) cholesterol were measured after 12 hours’ fasting, and participants were rested for 30 minutes before a sample was taken and conserved on ice. The sample has processed within 30 minutes of the blood draw.

2.4. Definition. Dyslipidemia was defined as disorders of lipoprotein metabolism with level of the total cholesterol (TC), LDL-C, TG, and level of HDL-C.

Lipoatrophy, a loss of subcutaneous fat, was defined by the presence of sunken cheeks with prominent zygomatic arch or thin extremities with prominent veins with or without buttock atrophy. Lipohypertrophy was defined as an increased abdominal girth or fat accumulation “buffalo hump.” Mixed form was defined if there was one or more signs of sign for each of lipoatrophy and lipohypertrophy [10].

According to the National Cholesterol Education Program, hypercholesterolemia was defined as a cholesterol concentration > 200 mg/dl and hypertriglyceridemia as a cholesterol concentration > 150 mg/dl, high HDL as a serum HDL concentration > 85 mg/dl, and LDL as a serum LDL concentration ≥ 130 mg/dl [11].

2.5. Ethical Consideration. Since all participants were minors, they provided assent and their legal guardians provided consent for study participation. This consent procedure was reviewed and approved by the National Ethical Committee of the Public Health School of the University of Kinshasa, Kinshasa, DRC.

2.6. Data Management and Statistical Analysis. The validated data were entered into the computer using EPI Info version 6.0 (CDC, Atlanta, Georgia, USA). The analysis was performed using SPSS version 20.0. Continuous variables were expressed as mean ± standard deviation (SD) or medians (range) and categorical variables as relative frequency in percent. Associations between variables of dyslipidemia and HIV category were evaluated using chi-square tests, Student’s t-tests, and Fisher’s exact tests. The level of significance was set as \( p < 0.05 \).
Table 1: Characteristics of the study population.

|                     | HIV-INFECTED+ ART  | Naive HIV-INFECTED | Negative HIV |
|---------------------|---------------------|--------------------|--------------|
|                     | n=80                | n=65               | n=80         |
| **Gender, n, (%)**  |                     |                    |              |
| Boys                | 39 (48.6)           | 33 (50.8)          | 39 (48.6)    |
| Girls               | 41 (51.4)           | 32 (49.2)          | 41 (51.4)    |
| **Clinical stages, n, (%)** |                 |                    |              |
| Stage A             | 0 (0)               | 62 (95.4)          | 0 (0)        |
| Stage B             | 66 (82.5)           | 3 (4.6)            | 0 (0)        |
| Stage C             | 14 (17.5)           | 0 (0)              | 0 (0)        |
| Stage D             | 0 (0)               | 0 (0)              | 0 (0)        |
| **BMI (kg/m^2) × n, (%)** |                |                    |              |
| Wasting < 15        | 23 (28.8)           | 22 (33.8)          | 10 (12.5)    |
| Thinness (15-18.4)  | 34 (42.5)           | 34 (52.3)          | 27 (33.8)    |
| Normal (18.5-24.9)  | 22 (27.5)           | 9 (13.8)           | 42 (52.5)    |
| Overweight (25-29.9)| 0 (0)               | 0 (0)              | 0 (0)        |
| Obesity ≥ 30        | 1 (1.2)             | 1 (1.5)            | 1 (1.2)      |
| **Triceps skinfold, n, (%)** |             |                    |              |
| P < 50              | 66 (82.5)           | 57 (87.7)          | 30 (37.5)    |
| P 50-90             | 13 (16.3)           | 8 (12.3)           | 49 (61.3)    |
| P >90               | 1 (1.2)             | 0 (0)              | 1 (1.2)      |

*p=0.001; **p>0.05.

Table 2: Distribution of lipodystrophy according to the type, location, and serostatus.

| Type                 | HIV+ ARVs n=80 | Negative HIV n=65 | Naive HIV+ n=65 | P     |
|----------------------|----------------|-------------------|-----------------|-------|
| **Lipoatrophy**      |                |                    |                 |       |
| (i) Ball of Bichat   | 2 (2.5)        | 0.00              | 0.00            | 0.124 |
| (ii) Fabric Fonte    |                |                    |                 |       |
| (a) Face             | 4 (5.0)        | 0.00              | 6 (9.2)         | 0.007 |
| (b) Members          | 4 (5.0)        | 0.00              | 5 (7.7)         | 0.016 |
| (c) buttocks         | 3 (3.8)        | 0.00              | 3 (4.6)         | 0.085 |
| **Lipohypertrophy**  |                |                    |                 |       |
| (i) neck             | 2 (2.5)        | 1 (1.2)           | 2 (3.0)         | 0.531 |
| (ii) Buffalo humps   | 2 (2.5)        | 0.00              | 0.00            | 0.124 |
| (iii) Breast adiposity| 2 (2.5)       | 1 (1.2)           | 1 (1.5)         | 0.824 |
| (iv) Abdominal obesity| 6 (7.5)       | 1 (1.2)           | 2 (3.0)         | 0.093 |
| **Mixed forms**      | 3 (3.8)        | 0.00              | 2 (3.0)         | 0.105 |

3. Results

Characteristics of the study participants are presented in Table 1. The majority of the children (66.7%) were between six and 12 years of age. The majority of the children on ARV therapy (92.5%) were on the first-line regimen containing a nonnucleoside reverse transcriptase inhibitor (AZT + 3TC + NVP (or EFV)). Lipodystrophy has been diagnosed in 16.3% in children on ARV therapy and 21.5% in HIV-infected antiretroviral therapy-naïve children. However, there was no statistically significant difference between the two groups. A significantly higher proportion (15%) of subjects with lipohypertrophy were children on ARV therapy, compared to 7.7% in HIV-infected antiretroviral therapy-naïve children (Table 1). Mixed form was rarely observed (Table 2). A significantly higher proportion (7.5%) of subjects with hypercholesterolemia were children on ARV therapy. No case of hypercholesterolemia was reported in HIV-infected antiretroviral therapy-naïve children (Table 1).
Table 3: Laboratory features in the study population according to serologic status and treatment.

|                        | HIV-Infected + ARV n(%) | Negative HIV n(%) | Naive HIV-infected n(%) | p     |
|------------------------|-------------------------|-------------------|-------------------------|-------|
| Cholesterol (mg/dl)    |                         |                   |                         |       |
| Hyper (> 200)          | 6 (7.5)                 | 1 (1.2)           | 0 (0.0)                 | 0.05  |
| HDL-Cholesterol (mg/dl)|                         |                   |                         |       |
| Hyper (> 150)          | 2 (2.5)                 | 1 (1.2)           | 1 (1.5)                 | 0.25  |
| Triglycerides (mg/dl)  |                         |                   |                         |       |
| Hyper (> 150)          | 13 (16.2)               | 4 (5.0)           | 7 (10.8)                | 0.136 |
| Dyslipidemia           |                         |                   |                         |       |
| Yes                    | 74 (92.5)               | 77 (96.2)         | 60 (92.3)               | 0.52  |
| No                     | 6 (7.5)                 | 3 (3.8)           | 5 (7.7)                 |       |

Hypertriglyceridemia was present in 16.2% of children on ARV therapy and in 7% of HIV-infected antiretroviral therapy-naïve children. However, this difference was not significant (Table 3).

4. Discussion

The assessment of dyslipidemia is imperative because the national policy on ARV treatment has not yet assessed the metabolic side effects of these drugs in pediatrics. Probably this impairment is underreported in African children; poverty and the paucity of pediatricians and cardiologists in our midst should contribute to this fact.

In our cohort, the majority of the children were on the first-line regimen containing a nonnucleoside reverse transcriptase inhibitor (AZT + 3TC + NVP (or EFV)). Until 2010, the World Health Organization’s (WHO) first-line regimen options for HIV-infected children included both stavudine and zidovudine. Although WHO guidelines no longer recommend it, many children in sub-Saharan Africa continue to receive stavudine as part of their cART regimen [12]. Furthermore, the difficulty of access to care explains the large number of children who do not receive antiretroviral treatment.

In this study, lipoatrophy was found in 16.3% in children on ARV therapy and 21.5% in HIV-infected antiretroviral therapy-naïve children. However, there was no statistically significant difference between the two groups. Children on ARV therapy face an increased risk of lipoatrophy due to this therapy particularly in regimen with nucleoside reverse transcriptase inhibitors leading to a loss of subcutaneous fat [13, 14]. The frequency of lipoatrophy in children on ARV therapy (16.3%) found in this study is similar to that reported in Tanzania with 19% of affected children [3, 5].

On the other hand, lipodystrophy has also been described in patients naïve to HIV protease inhibitors [15].

A significantly higher proportion (15%) of subjects with lipohypertrophy were children on ARV therapy, compared to 7.7% in HIV-infected antiretroviral therapy-naïve children and 3.8% in noninfected children. These differences in the relative frequency of the lipohypertrophy prevalence between the three groups presumably arise from differences in the risk of exposure to ARV therapy, which influence the risk of development of lipohypertrophy. Our findings reported in this study were similar to those described elsewhere [5, 16].

Mixed form was rarely observed in our cohort and was similar to those reported by previous studies [10].

A significantly higher proportion of subjects with hypercholesterolemia were children on ARV therapy, in this cohort. The prevalence of hypercholesterolemia is high among HIV-infected children on ARV therapy, in this cohort. This finding is similar to previous reports from elsewhere [6, 17–19]. A recent study showed the association between the APOC3 genotype and hypercholesterolemia in an HIV-1-infected pediatric cohort exposed to ARV therapy [20].

The proportion of hypertriglyceridemia tended to be higher among children on ARV therapy than in the other two groups. In this study, the proportion of HIV-infected children with ARV therapy diagnosed with hypertriglyceridemia was 16%, which is similar to other worldwide studies that have reported 12% to 25% [16, 19, 21] but lower than the 29% to 83% reported in other pediatric cohorts [6, 22–26].

In a recent study, the authors found a protective effect of lipoprotein lipase polymorphisms against hypertriglyceridemia in children under ARV therapy [27].

5. Conclusion

Metabolic disorders encountered in HIV-infected children have been described. The emergence of lipohypertrophy, hypercholesterolemia, and lactic acidosis is more common in HIV-infected children on ARV therapy than in normal controls. Furthermore, it appears that one in 5 HIV-infected children had lipoatrophy. Population-based surveillance is required for accurate data that should be used to measure the magnitude, the evolution, and the pattern of metabolic disorders HIV-infected children living in the DRC. These clinical and biological markers may guide the clinician in the decision to initiate specific antiretroviral therapy in high resource settings.

Data Availability

The data is available at the Department of Pediatrics of University of Kinshasa at the following contact: michelaloni2003@yahoo.fr.
Additional Points

Keynotes. (i) Very few studies focused on the prevalence of lipodystrophy in paediatric HIV patients on ARV therapy that have been reported in sub-Saharan African countries. (ii) A significantly higher proportion of lipohypertrophy, hypercholesterolemia, and lactic acidosis was noted among HIV-infected children on ARV therapy, compared to the controls. (iii) Given the high rate of the HIV/AIDS in sub-Saharan Africa, there is a real need to prevent and manage metabolic disorders in HIV-infected children in our midst.

Conflicts of Interest

The authors have no conflicts of interest to disclose.

Authors’ Contributions

Honoré Kalombayi Tshamala, Loukia Aketi, Patrick Kalambayi Kayembe, and Joseph Diaiyisu Shiku conceived, designed, deployed, and directed the case-control study at the Faculty of Medicine of University of Kinshasa. Honoré Kalombayi Tshamala carried out patient recruitment and follow-up, sample collection, storage, and transport. Honoré Kalombayi Tshamala, Loukia Aketi, and Michel Ntetani Aloni wrote the manuscript. Joseph Diaiyisu Shiku, Mathilde Bothale Ekila, and Michel Ntetani Aloni brought some precious corrections. Eric Musalu Mafuta, Patrick Kalambayi Kayembe, Honoré Kalombayi Tshamala, Loukia Aketi, Michel Ntetani Aloni, and Mathilde Bothale Ekila analyzed data. Honoré Kalombayi Tshamala, Loukia Aketi, Mathilde Bothale Ekila, and Michel Ntetani Aloni edited the English made corrections. All authors read and approved the final manuscript.

References

[1] L. Feinstein, A. Edmonds, J. L. Chalachala et al., “Temporal changes in the outcomes of HIV-exposed infants in Kinshasa, Democratic Republic of Congo during a period of rapidly evolving guidelines for care (2007–2013),” AIDS, vol. 28, pp. S301–S311, 2014.
[2] R. J. Kim and R. M. Rutstein, “Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients,” Pediatric Drugs, vol. 12, no. 3, pp. 187–199, 2010.
[3] L. Papi, A. C. Menezes, H. Rocha et al., “Prevalence of lipodystrophy and risk factors for dyslipidemia in HIV-infected children in Brazil,” The Brazilian Journal of Infectious Diseases, vol. 18, no. 4, pp. 394–399, 2014.
[4] “UNAIDS Global report: UNAIDS report on the global AIDS epidemic 2013.”
[5] G. D. Kinabo, M. Sprengers, L. J. Msuya et al., “Prevalence of lipodystrophy in hiv-infected children in Tanzania on highly active antiretroviral therapy,” The Pediatric Infectious Disease Journal, vol. 32, no. 1, pp. 39–44, 2013.
[6] T. Piloya, S. Bakeera-Kitaka, A. Kekitiinwa, and M. R. Kamya, “Lipodystrophy among HIV-infected children and adolescents on highly active antiretroviral therapy in Uganda: a cross sectional study,” Journal of the International AIDS Society, vol. 15, no. 2, 2012.
[7] M. Bwakura-Dangarembizi, V. Musiime, A. J. Szubert et al., “Prevalence of Lipodystrophy and Metabolic Abnormalities in HIV-infected African Children after 3 Years on First-line Antiretroviral Therapy,” The Pediatric Infectious Disease Journal, vol. 34, no. 2, pp. e23–e31, 2015.
[8] R. A. Amaya, C. A. Kozinetz, A. McMeans, H. Schwarzwald, and M. W. Kline, “Lipodystrophy syndrome in human immunodeficiency virus-infected children,” The Pediatric Infectious Disease Journal, vol. 21, no. 5, pp. 405–410, 2002.
[9] WHO, Antiretroviral Therapy of HIV Infection in Infants and Children in Resource-Limited Settings: Towards Universal Access: Recommendations for a Public Health Approach, Geneva, Switzerland, 2006.
[10] A. M. Sánchez Torres, R. Munoz Muniz, R. Madero, C. Borque, M. J. García-Miguel, and M. I. De José Gómez, “Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children,” European Journal of Pediatrics, vol. 164, no. 5, pp. 271–276, 2005.
[11] DART Trial Team, “Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial,” The Lancet, vol. 375, no. 9709, pp. 123–131, 2010.
[12] M. Palmer, M. Chersich, H. Moultrie, L. Kuhn, L. Fairlie, and T. Meyers, “Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa,” AIDS, vol. 27, no. 5, pp. 781–785, 2013.
[13] S. Innes, M. F. Cotton, R. Haubrich et al., “High prevalence of lipoatrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study,” BMC Pediatrics, vol. 12, no. 1, 2012.
[14] K. Hartman, G. Verweel, R. De Groot, and N. G. Hartwig, “Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy,” The Pediatric Infectious Disease Journal, vol. 25, no. 5, pp. 427–431, 2006.
[15] S. Madge, S. Kinloch-de-Loes, D. Mercery, M. A. Johnson, and I. V. D. Heller, “Lipodystrophy in patients naive to HIV protease inhibitors,” AIDS, vol. 13, no. 6, pp. 735–737, 1999.
[16] L. Aupribul, T. Puthanakit, B. Lee, A. Mangklabruks, T. Sirisanthana, and V. Sirisanthana, “Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy,” Antiviral Therapy, vol. 12, no. 8, pp. 1247–1254, 2007.
[17] S. Rusconi, V. Giacomet, C. Mameli et al., “Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population,” BMC Infectious Diseases, vol. 12, no. 1, 2012.
[18] S. Kanjanavanit, T. Puthanakit, U. Vibo et al., “High prevalence of lipid abnormalities among antiretroviral-naive HIV-infected Asian children with mild-to-moderate immunosuppression,” Antiviral Therapy, vol. 16, no. 8, pp. 1351–1355, 2011.
[19] M. Dapena, B. Jiménez, A. Noguera-Julian et al., “Metabolic disorders in vertically HIV-infected children: Future adults at risk for cardiovascular disease,” Journal of Pediatric Endocrinology and Metabolism, vol. 25, no. 5–6, pp. 529–535, 2012.
[20] C. A. Rocco, D. Mecikovsky, P. Aulicino et al., “Hypercholesterolemia Is Associated with the Apolipoprotein C-III (APOC3) Genotype in Children Receiving HAART: An Eight-Year Retrospective Study,” PLoS ONE, vol. 7, no. 7, Article ID e39678, 2012.
[21] European Paediatric Lipodystrophy Group, “Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe,” *AIDS*, vol. 18, no. 10, pp. 1443–1451, 2004.

[22] M. Brewinski, K. Megazzini, L. Freimanis Hance et al., “Dyslipidemia in a cohort of HIV-infected Latin American children receiving highly active antiretroviral therapy,” *Journal of Tropical Pediatrics*, vol. 57, no. 5, pp. 324–332, 2011.

[23] V. Briz, C. Palladino, M. Navarro et al., “Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients,” *HIV Medicine*, vol. 12, no. 7, pp. 442–446, 2011.

[24] T. Bunupuradah, T. Puthanakit, P. Fahey et al., “Second-line protease inhibitor-based highly active antiretroviral therapy after failing non-nucleoside reverse transcriptase inhibitor-based regimens in Asian HIV-infected children,” *Antiviral Therapy*, vol. 18, no. 4, pp. 591–598, 2013.

[25] P. Dejkhamron, K. Unachak, L. Aurbibul, and V. Sirisanthana, “Insulin resistance and lipid profiles in HIV-infected Thai children receiving lopinavir/ritonavir-based highly active antiretroviral therapy,” *Journal of Pediatric Endocrinology and Metabolism*, vol. 27, no. 5-6, 2014.

[26] F. Solórzano Santos, L. G. Gochicoa Rangel, G. Palacios Saucedo, G. Vázquez Rosales, and M. G. Miranda Novales, “Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors,” *Archives of Medical Research*, vol. 37, no. 1, pp. 129–132, 2006.

[27] C. Colombo, G. Catano, C. A. Rocco et al., “Role of 3 Lipoprotein Lipase Variants in Triglycerides in Children Receiving Highly Active Antiretroviral Therapy,” *The Pediatric Infectious Disease Journal*, vol. 34, no. 2, pp. 155–161, 2015.